Table 1 The anti-proliferation activities of lycorine and lycorine hydrochloride in vitro
Cancer type | Cell line | Time (h) | Method | IC50 (μM) | Reference |
|---|---|---|---|---|---|
Bladder cancer | T24 | 72 | CCK-8 |  ~ 1 | [39] |
5673 | 72 | CCK-8 |  ~ 1 | ||
Bladder cancer | T24 | 48 | MTT | 7.5 | [40] |
Breast cancer | BT-549 | 48 | CCK-8 | 1.1 | [17] |
MCF-7 | 48 | CCK-8 | 0.8 | ||
MDA-MB-231 | 48 | CCK-8 | 1.4 | ||
Breast cancer | MDA-MB-231 | 48 | SRB | 0.9 | [41] |
MDA-MB-468 | 48 | SRB | 1.4 | ||
MCF-7 | 48 | SRB | 0.7 | ||
Breast cancer | MCF-7 | 48 | SRB | 0.5–2 | [42] |
T47D | 48 | SRB | 2–5 | ||
MDA-MB-231 | 48 | SRB | 5–10 | ||
4T1 | 48 | SRB | 2–5 | ||
Breast cancer | MDA-MB-231 | 48 | CCK-8 | 40–60 | [43] |
MCF-7 | 48 | CCK-8 | 40–60 | ||
Breast cancer | MDA-MB-231 | 24 | MTT | 1.9 | [36] |
MCF-7 | 24 | MTT | 7.8 | ||
B-cell acute lymphoblastic leukemia | REH | 72 | MTS | 1.6 | [44] |
NALM-6 | 72 | MTS | 1.9 | ||
Cervical cancer | HeLa | 48 | CCK-8 | 0.9 | [17] |
Cervical cancer | HT-3 | 24 | MTT | 40.0 | [45] |
Colorectal cancer | HCT116 | 72 | MTT | 1.4 | [73] |
LoVo | 72 | MTT | 3.8 | ||
SW480 | 72 | MTT | 1.3 | ||
Colorectal cancer | COLO-201 | 48 | CCK-8 | 0.8 | [17] |
HT-29 | 48 | CCK-8 | 0.8 | ||
SW-480 | 48 | CCK-8 | 0.9 | ||
Gastric cancer | AGS | 48 | CCK-8 | 0.8 | [17] |
Glioma | C6 | 48 | MTT | 2.9 | [48] |
Liver cancer | HepG2 | 48 | MTT | 2.6 | [52] |
| Â | Huh-7 | 48 | MTT | 2.0 | Â |
Liver cancer | HepG2 | 48 | MTT | 2–10 | [50] |
Liver cancer | HepG2 | 48 | MTT | 34.1 | [51] |
SMMC-7721 | 48 | MTT | 36.6 | ||
Huh-7 | 48 | MTT | 38.3 | ||
Leukemia | HL-60 | 24 | MTT |  ~ 1 | [53] |
Leukemia | HL-60 | 48 | CCK-8 | 1.3 | [17] |
Jurkat | 48 | CCK-8 | 1.3 | ||
MOLT-4 | 48 | CCK-8 | 1.0 | ||
Glioblastoma multiforme | U251 | 48 | SRB | 10–20 | [54] |
U87 | 48 | SRB | 10–20 | ||
A172 | 48 | SRB | 10–20 | ||
LN299 | 48 | SRB | 10–20 | ||
Lung cancer | SPC-A-1 | 72 | CTG | 4.8 | [55] |
A549 | 72 | CTG | 4.0 | ||
Lung cancer | A549 | 24 | MTT | 10.8 | [56] |
H460 | 24 | MTT | 12.4 | ||
Lung cancer | A549 | 24 | CCK-8 | 5–10 | [57] |
H1299 | 24 | CCK-8 | 10–20 | ||
Lung cancer | A549 | 48 | CCK-8 | 1.0 | [17] |
H1299 | 48 | CCK-8 | 0.9 | ||
Melanoma | A375 | 48 | MTT |  ~ 20 | [58] |
MV3 | 48 | MTT |  ~ 20 | ||
Melanoma | A375 | 72 | CCK-8 |  ~ 50 | [59] |
Myeloma | ANBL6 | 24 | CCK-8 | 2.5–5 | [61] |
MM.1S | 24 | CCK-8 |  ~ 10 | ||
Oral cancer | HSC-3 | 48 | CCK-8 | 6.2 | [62] |
HSC-4 | 24 | CCK-8 | 48.6 | ||
UM1 | 24 | CCK-8 | 35.3 | ||
UM2 | 24 | CCK-8 | 28.0 | ||
Osteosarcoma | Saos-2 | 48 | CCK-8 | 1.2 | [17] |
Osteosarcoma | HOS | 24 | CCK-8 | 3.0 | [63] |
MG63 | 24 | CCK-8 | 2.5 | ||
U2OS | 24 | CCK-8 | 1.4 | ||
SJSA-1 | 24 | CCK-8 | 1.9 | ||
Osteosarcoma | 143B | 48 | MTT | 3.2 | [64] |
MG63 | 48 | MTT | 5.5 | ||
Saos-2 | 48 | MTT | 2.9 | ||
U2OS | 48 | MTT | 3.2 | ||
Osteosarcoma | MNNG/HOS | 48 | CCK-8 | 1–2 | [65] |
U2OS | 48 | CCK-8 |  ~ 2, | ||
MG63 | 48 | CCK-8 |  ~ 2 | ||
Saos-2 | 48 | CCK-8 |  ~ 2 | ||
Ovarian cancer | A2780 | 48 | CCK-8 | 1.2 | [17] |
Ovarian cancer | Hey1B | 48 | AlamarBlue | 1.2 | [66] |
Pancreatic cancer | Panc-1 | 72 | CTG | 1.0 | [67] |
Patu8988 | 72 | CTG | 1.5 | ||
Pancreatic cancer | PANC-1 | 48 | CCK-8 | 0.7 | [17] |